Categories: BrainDiagnosticsNews

Nexstim Plc’s Financial Information in 2023

Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET)

Nexstim Plc’s Financial Information in 2023

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it will publish the following financial information in 2023:

The 2022 Financial Statements Release and Half-Yearly Report July−December 2022 (H2) on Monday, February 27, 2023. Half-Yearly Report January-June 2023 (H1) on Friday, August 11, 2023.

Nexstim’s Annual Report 2022 will be published and available on the Company’s website on Monday, March 6, 2023.

The Annual General Meeting is tentatively scheduled to be held on Friday March 31, 2023 at 10:00 am.

NEXSTIM PLC        

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

2 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

2 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

2 hours ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

2 hours ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

2 hours ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

2 hours ago